NASDAQ · Financial Statements

City Therapeutics, Inc. (CTY) Financial Statements

$20.77 NASDAQ: CTY Market Cap $201.93M

City Therapeutics, Inc. most recently reported annual revenue of $8.2B, net profit of $1.8B. Revenue declined at an average annual rate of 1.6% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

City Therapeutics, Inc.: Revenue fell from $9.3B in 2010 to $8.2B in 2019, a change of -12.0% over 9 years; net profit was positive in all 10 reported years; operating margin moved from 26.8% to 35.4%, a shift of +8.6 percentage points; the most recent year shows net profit of $1.8B.

Income Statement — 10 Years (USD millions)

Metric	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Revenue	$9.3B	$6.6B	$8.8B	$8.8B	$8.8B	$9.0B	$8.9B	$8.6B	$8.5B	$8.2B
Operating Expenses	$6.8B	$5.4B	$6.9B	$6.7B	$6.7B	$6.7B	$6.6B	$6.2B	$5.8B	$5.3B
Operating Profit	$2.5B	$1.2B	$1.9B	$2.1B	$2.1B	$2.3B	$2.3B	$2.3B	$2.7B	$2.9B
Operating Margin	26.8%	18.1%	21.5%	23.7%	23.9%	25.2%	26.1%	27.1%	31.3%	35.4%
Other Income	$-610.0M	$-307.0M	$-514.0M	$-512.0M	$-503.0M	$-527.0M	$-559.0M	$-522.0M	$-501.0M	$-416.0M
Interest	$615.0M	$0	$443.0M	$450.0M	$464.0M	$473.0M	$478.0M	$465.0M	$448.0M	$0
Depreciation	$1.9B	$1.9B	$2.2B	$2.1B	$2.0B	$1.8B	$1.7B	$1.6B	$1.4B	$1.4B
Profit Before Tax	$1.9B	$892.0M	$1.4B	$1.6B	$1.6B	$1.7B	$1.8B	$1.8B	$2.2B	$2.5B
Tax	$42.2M	$39.1M	$39.0M	$38.4M	$39.7M	$38.0M	$38.5M	$7.5M	$22.9M	$26.0M
Net Profit	$1.1B	$543.0M	$849.0M	$964.0M	$970.0M	$1.1B	$1.1B	$1.7B	$1.7B	$1.8B
EPS	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Dividend Payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

Metric	Sep '17	Dec '17	Mar '18	Jun '18	Sep '18	Dec '18	Mar '19	Jun '19	Sep '19	Dec '19	Mar '20	Jun '20
Revenue	$2.1B	$2.1B	$2.1B	$2.1B	$2.1B	$2.1B	$2.1B	$2.1B	$2.0B	$2.0B	$1.9B	$524.0M
Operating Expenses	$1.6B	$1.5B	$1.5B	$1.5B	$1.4B	$1.4B	$1.3B	$1.3B	$1.3B	$1.4B	$1.1B	$-155.0M
Operating Profit	$560.0M	$600.0M	$632.0M	$626.0M	$717.0M	$685.0M	$760.0M	$750.0M	$748.0M	$626.0M	$779.0M	$679.0M
Operating Margin	26.2%	28.4%	29.7%	29.8%	33.4%	32.4%	37.0%	36.6%	36.7%	31.1%	40.6%	129.6%
Interest	$117.0M	$117.0M	$118.0M	$120.0M	$112.0M	$98.0M	$95.0M	$96.0M	$95.0M	$286.0M	$0	$0
Profit Before Tax	$433.0M	$468.0M	$510.0M	$508.0M	$564.0M	$577.0M	$658.0M	$644.0M	$643.0M	$523.0M	$680.0M	$583.0M
Tax	$38.8M	$-80.8M	$25.5M	$15.9M	$19.7M	$29.8M	$26.0M	$25.9M	$25.8M	$26.2M	$26.0M	$26.2M
Net Profit	$265.0M	$846.0M	$380.0M	$427.0M	$453.0M	$405.0M	$487.0M	$477.0M	$477.0M	$386.0M	$503.0M	$430.0M
EPS	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00

Over the 10 years reported for City Therapeutics, Inc., borrowings decreased from $7.2B in 2010 to $6.0B in 2019, cash stood at $2.0M in the latest year, shareholders' equity was $10.1B, current assets covered current liabilities 0.73 times.

Balance Sheet — 10 Years (USD millions)

Metric	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Total Assets	$221.0M	$17.4B	$16.7B	$16.0B	$22.5B	$21.5B	$21.1B	$20.9B	$20.6B	$21.0B
Current Assets	$1.5B	$1.2B	$1.6B	$1.8B	$1.8B	$1.6B	$1.7B	$1.8B	$1.8B	$2.5B
Cash	$5.0M	$3.0M	$8.0M	$14.0M	$6.0M	$3.0M	$5.0M	$1.0M	$5.0M	$2.0M
Inventory	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Receivables	$-22.0M	$712.0M	$709.0M	$738.0M	$740.0M	$688.0M	$700.0M	$646.0M	$546.0M	$514.0M
Fixed Assets	$-1.2B	$7.5B	$7.2B	$7.2B	$7.2B	$7.4B	$7.6B	$7.9B	$8.1B	$8.2B
Capital Work in Progress	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Other Assets	$0	$9.5B	$9.4B	$9.4B	$9.4B	$9.4B	$9.4B	$9.4B	$9.4B	$9.4B
Total Liabilities	$14.5B	$15.0B	$14.0B	$13.6B	$13.3B	$12.6B	$12.5B	$11.5B	$10.7B	$10.9B
Current Liabilities	$3.2B	$2.1B	$2.8B	$2.7B	$2.3B	$2.4B	$2.8B	$2.2B	$2.3B	$3.4B
Borrowings	$7.2B	$8.3B	$7.6B	$7.6B	$7.4B	$7.2B	$7.3B	$7.3B	$6.0B	$6.0B
Other Liabilities	$7.3B	$6.7B	$6.3B	$6.0B	$5.9B	$5.3B	$5.2B	$4.3B	$4.8B	$4.9B
Equity	$11.4B	$10.0B	$10.1B	$10.1B	$10.1B	$10.1B	$10.1B	$10.1B	$10.1B	$10.1B
Reserves	$-831.0M	$9.9B	$10.0B	$9.6B	$9.2B	$8.9B	$8.7B	$9.3B	$9.9B	$10.1B

For City Therapeutics, Inc., operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $2.3B; free cash flow was positive in 10 of 10 years; financing activities used $14.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Operating Cash Flow	$3.2B	$2.2B	$2.8B	$2.7B	$2.8B	$2.6B	$2.7B	$2.4B	$3.8B	$3.3B
Investing Cash Flow	$-2.5B	$-1.0B	$-2.8B	$-2.6B	$-2.4B	$-2.5B	$-2.6B	$-2.8B	$-2.2B	$-2.8B
Financing Cash Flow	$-541.0M	$-311.0M	$-99.0M	$-15.0M	$-164.0M	$-27.0M	$-21.0M	$-4.0M	$-1.4B	$-14.0M
Net Cash Flow	$-822.0M	$-198.0M	$5.0M	$6.0M	$-8.0M	$-3.0M	$2.0M	$-4.0M	$2.0M	$-5.0M
Free Cash Flow	$2.0B	$1.2B	$1.5B	$1.4B	$1.6B	$1.3B	$1.4B	$1.1B	$2.8B	$2.3B

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	1.61
FCF Yield	1045.56%
Quick Ratio	0.73
Interest Coverage	—
Return 1Y	—
Return 3Y	—
Return 5Y	—

City Therapeutics, Inc. (CTY) financials — frequently asked questions

What is City Therapeutics, Inc.'s annual revenue?

City Therapeutics, Inc. (CTY) reported annual revenue of $8.2B in its most recent fiscal year.

What is City Therapeutics, Inc.'s net profit?

City Therapeutics, Inc. (CTY) reported net profit of $1.8B in its most recent fiscal year.

What is CTY EV/EBITDA?

City Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 1.61.

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

CTY Overview CTY Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.